Abstract
BackgroundAcquired drug resistance is one of the major reasons for failing cancer therapies. Although the reasons are not fully understood, they may be related to the presence of cancer stem cells (CSCs). We have reported that chemo-resistant (CR) colon cancer cells, highly enriched in CSCs, exhibit a marked up-regulation of miR-21 and that down-regulation of this miR renders the CR cells more susceptible to therapeutic regimens. However, the underlying molecular mechanism is poorly understood. The aim of this investigation is to unravel this mechanism.MethodsThe levels of miR-145 and miR-21 were manipulated by transfection of mature, antago-miRs or pCMV/miR-145 expression plasmid. Quantitative RT-PCR or/and Western blots were performed to examine the expression of CD44, β-catenin, Sox-2, PDCD4, CK-20 and k-Ras. Colonosphere formation and SCID mice xenograft studies were performed to evaluate the tumorigenic properties of CSC-enriched colon CR cells.ResultsWe investigated the role that microRNAs (miRs), specifically miR-21 and miR-145 play in regulating colon CSCs. We found the expression of miR-21 to be greatly increased and miR-145 decreased in CR colon cancer cells that are highly enriched in CSC, indicating a role for these miRNAs in regulating CSCs. In support of this, we found that whereas forced expression of miR-145 in colon cancer cells greatly inhibits CSCs and tumor growth, up-regulation of miR-21 causes an opposite phenomenon. In addition, administration of mature miR-145 or antagomir-21 (anti-sense miR-21) greatly suppresses the growth of colon cancer cell xenografts in SCID mice. This was associated with decreased expression of CD44, β-catenin, Sox-2 and induction of CK-20 indicating that administration of miR-145 or antagomir-21 decreases CSC proliferation and induces differentiation. In vitro studies further demonstrate that miR-21 negatively regulates miR-145 and vice versa. k-Ras appears to play critical role in regulation of this process, as evidenced by the fact that the absence of k-Ras in CR colon cancer cells increases miR-145 expression, suppresses miR-21, and interrupts the negative cooperation between miR-21 and miR-145.ConclusionsOur current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance.
Highlights
Acquired drug resistance is one of the major reasons for failing cancer therapies
We have reported that 5-Fluorouracil and Oxaliplatin (FUOx) resistant [chemo-resistant (CR)] colon cancer HCT116 and HT29 cells exhibit enrichment of cancer stem cells (CSCs)/CSLCs, elevated levels of mature miR-21 and that miR-21 induces stemness in colon cancer cells [7,8]
Over-expression of miR-145 induces differentiation, inhibits stemness and xenograft tumors in severe combined immunodeficient mice (SCID) mice More than 80% of colorectal cancers arise from adenomatous polyps that are known to contain CSCs/CSLCs [6] and dysregulation of miRNAs [16]
Summary
Acquired drug resistance is one of the major reasons for failing cancer therapies. The reasons are not fully understood, they may be related to the presence of cancer stem cells (CSCs). The underlying molecular mechanism is poorly understood. The aim of this investigation is to unravel this mechanism. The higher recurrence of CRC is thought to be the result of drug-resistance of cancer cells. The reasons for drug resistance are CSCs/CSLCs are a small population of self-renewing undifferentiated cells within a tumor that have been shown to be resistant to radiation and chemotherapy [2]. CSCs/ CSLCs isolated from different solid tumors, including the colon are usually identified by specific surface epitopes. We have observed that in humans, colon CSCs/CSLCs are present in premalignant adenomas and in normal appearing colonic mucosa and that the population of CSCs/CSLCs increases with advancing age, suggesting that they may be partly responsible for the age-related rise in colorectal cancer [6]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have